Search Medical Condition
Please enter condition
Please choose location

Elkhorn, Nebraska Clinical Trials

A listing of Elkhorn, Nebraska clinical trials actively recruiting patient volunteers.

RESULTS

Found (135) clinical trials

This is a randomized, double-blind, placebo-controlled, multicenter phase III study. The study population will consist of approximately 1300 subjects with metastatic hormone sensitive prostate cancer (mHSPC), who will be randomized (1:1 ratio) to receive 600 mg (2 x 300 mg tablets) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to ...

Phase

3.56 miles

Learn More »

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

This is a non-randomized, open-label, Phase 1/2 trial of VT-464 in patients with AR (+) TNBC or ER (+)/HER2 normal unresectable locally advanced MBC. . Phase 2 is an open-label, multi-center study and divided into parallel cohorts: AR (+) TNBC and ER (+) BC patients at the RP2D confirmed/established in ...

Phase

3.99 miles

Learn More »

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study will be conducted in two parts. Phase 1b is dose escalation in which patients are tested with SD-101 at various doses in combination with 200 mg pembrolizumab in patients with metastatic melanoma. Phase 2 will consist of 4 expansion cohorts to evaluate the efficacy and safety of SD-101 ...

Phase

4.83 miles

Learn More »

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas

PRIMARY OBJECTIVES: I. To determine the activity of a smoothened, frizzled class receptor (SMO) and PTCH1 inhibitor in patients with meningiomas harboring SMO mutations as measured by 6-month progression free survival (PFS) and response rate. II. To determine the activity of a FAK inhibitor in patients with meningiomas harboring neurofibromin ...

Phase

4.83 miles

Learn More »

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK) **Please note that the study is no longer enrolling patients for Groups A, B, C, and E.

Phase

4.83 miles

Learn More »